Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Decision on Norwegian PET (positron emission tomography) delayed

This article was originally published in Clinica

Executive Summary

Although the cost of introducing PET to Norway would be relatively high, its health benefits are obvious, says the leader of the Norwegian health and social committee, John Alvheim. He questioned why Norway's Scandinavian partners, Sweden and Denmark, had been using PET for some 20 years, but Norwegian cancer patients were not given access to the technology. "The number of people we could treat with this equipment would be several times the amount we currently do, using CT and MRI," said Mr Alvheim.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel